Bavachin

SKU: orb1303672

Description

Bavachin

Research Area

Metabolism Research

Key Properties

• CAS Number: 19879-32-4
• MW: 324.37
• Purity: 99.94%
• Formula: C₂₀H₂₀O₄
• SMILES: CC(C)=CCc1cc2C(=O)C[C@H](Oc2cc1O)c1ccc(O)cc1
• Target: Estrogen/progestogen Receptor,Estrogen Receptor/ERR
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (6.17 mM);DMSO:58 mg/mL (178.81 mM);Chloroform, Dichloromethane, Ethyl Acetate:Soluble

Bioactivity

• Target IC50:
  ERβ:680 nM (EC50)|ERα:32 nM (EC50)
• In Vitro:
  Bavachin effectively reduces melanin production and tyrosinase (TYR) activity. At a concentration of 10 μM, it inhibits not only TYR and c-Jun N-terminal kinase (JNK) protein expression but als the expression of TYR, tyrosinase-related protein-1 (TRP-1), TRP-2, extracellular signal-regulated kinase 1 (ERK1), ERK2, and JNK2 mRNA in A375 cells the effects of bavachin on protein and mRNA expression levels of TYR, TRP-1, TRP-2, ERK1, ERK2, and JNK2 are significantly reversed by ICI182780 and U0126. furthermore , bavachin promotes lipid accumulation in a dose-dependent manner, evident in Oil Red O (ORO) staining experiments, and enhances preadipocyte growth at 10 μM, as demonstrated in MTT assay, compared to control cells. It also boosts bromodeoxyuridine (BrdU) incorporation into newly synthesized DNA during pre-adipocyte proliferation, a process further enhanced by Insulin and by co-treatment with Insulin and bavachin. Bavachin activates adipogenic factors, increases peroxisome proliferator-activated receptor gamma (PPARγ) transcriptional activity in differentiated adipocytes, and improves insulin-stimulated glucose uptake through glucose transporter type 4 (GLUT4) translocation vi the Akt and AMP-activated protein kinase (AMPK) pathways. Additionally, bavachin significantly increases human monoamine oxidase-A (hMAO-A) and hMAO-B activities. It also exhibits estrogen receptor (ER) li and-binding activity, displacing [3H] estradiol (E2) from recombinant ER, with its estrogenic activity characterized by half-maximal effective concentration (EC50) of 320 nM for ERα and 680 nM for ERβ in a transient transfection system. Bavachin upregulates mRNA levels of estrogen-responsive genes such as pS2 and PR, while decreasing ERα protein level vi the proteasomal pathway.
• Cell Research:
  Bavachin is dissolved in DMSO. MTT solution (20 μL) is added to each well o the 96-well plates the cells are cultured for 4 h the solution is discarded, an the purple crystal is dissolved in the wells with 150 μL DMSO solution, agitated in a 37°C incubator shaker for 10 min, an the optical density (OD) is measured at 490 nM b the microplate reader.

Storage & Handling

• Storage: keep away from direct sunlight,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Estrogen Receptor/ERR, EstrogenReceptor, Estrogen Receptor, ERR, ERα, ERβ, Inhibitor, inhibit, Corylifolin, Bavachin, progestogen Receptor, progestogenReceptor

Compound Identifiers

PubChem CID

14236566